Policy | August 06, 2021
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
CDSCO to fast-track trials and approval for COVID19 vaccine
CDSCO to fast-track trials and approval for COVID19 vaccine
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Complementary business models are the reason for the acquisition
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Subscribe To Our Newsletter & Stay Updated
